COVIDSeq Test (RUO and PEO Versions)

This high-throughput next-generation sequencing (NGS) assay detects RNA from the SARS-CoV-2 virus.Read More...

 

Key Features and Benefits
  • Accuracy: Detects 98 targets on SARS-CoV-2 for highly accurate detection
  • Throughput: 3072 results in 12 hours on the NovaSeq 6000 System
  • Quality Control: Internal control consists of 11 human mRNA targets in every reaction.

Product Highlights

The Illumina COVIDSeq Test (RUO and PEO versions), an amplicon-based NGS assay, includes 2019-nCoV primer and probe sets designed to detect RNA from the SARS-CoV-2 virus for clinical research applications.

Rapid, Scalable SARS-CoV-2 Detection

The Illumina COVIDSeq Test (RUO and PEO versions) can be scaled up or down to accommodate different numbers of samples. Up to 3072 results can be processed in 12 hours on the NovaSeq 6000 System using two NovaSeq 6000 S4 Reagent Kits with the Xp workflow.

Workflow and Components

The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. Key components include the high-throughput NovaSeq 6000 System, coupled with the Illumina COVIDSeq Test (RUO and PEO versions) and the DRAGEN COVIDSeq Test Pipeline (RUO) for rapid reporting.

Design and Quality Control

The Illumina COVIDSeq Test (RUO and PEO versions) leverages a modified version of the validated, publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. As a quality feature, an internal control consisting of 11 human mRNA targets is included in every sample to monitor for errors.

Frequently Purchased Together

Specifications

High-Level Workflow